Annual report pursuant to Section 13 and 15(d)

Segment reporting (Details) - Schedule of financial information represents the operating results of the reportable segments

v3.21.2
Segment reporting (Details) - Schedule of financial information represents the operating results of the reportable segments - USD ($)
$ in Thousands
 12 Months Ended
Jul. 31, 2021
Jul. 31, 2020
Jul. 31, 2019
Clinical Laboratory Services [Member]      
Segment Reporting Information [Line Items]      
Revenues $ 86,984 $ 47,964 $ 51,115
Grant income   1,496  
Total   49,460  
Cost of revenues 48,179 38,855 44,226
Research and development 615 1,509 31
Selling, general and administrative 26,028 23,533 24,230
Legal and related expenses 264 211 159
Legal settlements, net    
Total operating costs and expenses 75,086 64,108 68,646
Operating income (loss) 11,898 (14,648) (17,531)
Interest (17) (36) (64)
Other (18) 45 16
Foreign exchange gain (loss)
Income (loss) before taxes 11,863 (14,639) (17,579)
Depreciation and amortization included above 1,609 1,553 1,625
Capital expenditures 3,352 1,811 1,374
Life Sciences Products [Member]      
Segment Reporting Information [Line Items]      
Revenues 30,747 26,561 30,055
Grant income    
Total   26,561  
Cost of revenues 15,975 13,396 13,696
Research and development 2,559 2,190 2,257
Selling, general and administrative 11,015 10,485 11,860
Legal and related expenses 25 2 27
Legal settlements, net     (28,925)
Total operating costs and expenses 29,574 26,073 (1,085)
Operating income (loss) 1,173 488 31,140
Interest 37 56 67
Other 7 13 2
Foreign exchange gain (loss) 270 905 (682)
Income (loss) before taxes 1,487 1,462 30,527
Depreciation and amortization included above 756 964 1,221
Capital expenditures 752 322 605
Therapeutics [Member]      
Segment Reporting Information [Line Items]      
Revenues
Grant income    
Total    
Cost of revenues
Research and development 78 749 887
Selling, general and administrative 62
Legal and related expenses
Legal settlements, net    
Total operating costs and expenses 140 749 887
Operating income (loss) (140) (749) (887)
Interest
Other
Foreign exchange gain (loss)
Income (loss) before taxes (140) (749) (887)
Depreciation and amortization included above
Capital expenditures
Other [Member]      
Segment Reporting Information [Line Items]      
Revenues
Grant income    
Total    
Cost of revenues
Research and development
Selling, general and administrative 7,800 8,942 8,175
Legal and related expenses 4,439 6,516 2,814
Legal settlements, net    
Total operating costs and expenses 12,239 15,458 10,989
Operating income (loss) (12,239) (15,458) (10,989)
Interest (12) 434 1,053
Other 6,916 430 364
Foreign exchange gain (loss)
Income (loss) before taxes (5,335) (14,594) (9,572)
Depreciation and amortization included above 288 263 190
Capital expenditures 332 37 6,147
Consolidated [Member]      
Segment Reporting Information [Line Items]      
Revenues 117,731 74,525 81,170
Grant income   1,496  
Total   76,021  
Cost of revenues 64,154 52,251 57,922
Research and development 3,252 4,448 3,175
Selling, general and administrative 44,905 42,960 44,265
Legal and related expenses 4,728 6,729 3,000
Legal settlements, net     (28,925)
Total operating costs and expenses 117,039 106,388 79,437
Operating income (loss) 692 (30,367) 1,733
Interest 8 454 1,056
Other 6,905 488 382
Foreign exchange gain (loss) 270 905 (682)
Income (loss) before taxes 7,875 (28,520) 2,489
Depreciation and amortization included above 2,653 2,780 3,036
Capital expenditures 4,436 2,170 8,126
Selling, General and Administrative Expenses [Member] | Clinical Laboratory Services [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation 33 57 147
Selling, General and Administrative Expenses [Member] | Life Sciences Products [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation 102 74 95
Selling, General and Administrative Expenses [Member] | Therapeutics [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation
Selling, General and Administrative Expenses [Member] | Other [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation 679 756 697
Selling, General and Administrative Expenses [Member] | Consolidated [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation 814 887 939
Cost of Sales [Member] | Clinical Laboratory Services [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation 93 46  
Cost of Sales [Member] | Life Sciences Products [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation  
Cost of Sales [Member] | Therapeutics [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation  
Cost of Sales [Member] | Other [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation  
Cost of Sales [Member] | Consolidated [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation 93 46  
Total [Member] | Clinical Laboratory Services [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation 126 103 147
Total [Member] | Life Sciences Products [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation 102 74 95
Total [Member] | Therapeutics [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation
Total [Member] | Other [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation 679 756 697
Total [Member] | Consolidated [Member]      
Segment Reporting Information [Line Items]      
Share-based compensation $ 907 $ 933 $ 939